Navigation Links
Boehringer Ingelheim's investigational volasertib receives FDA Breakthrough Therapy designation
Date:9/17/2013

to advance Plk inhibitors into clinical development.

Volasertib is designed to inhibit the activity of Plk1, an enzyme in the Plk family that regulates cell division (mitosis).  This inhibition is intended to result in prolonged cell cycle arrest, ultimately leading to cell death (apoptosis).10

Volasertib* is not approved by the FDA; its safety and efficacy have not been established.

About Boehringer Ingelheim in Oncology
Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to discover and develop innovative cancer treatments.  Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers. The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition. The company is also evaluating a robust and growing pipeline of early-stage oncology compounds in areas including growth/survival signaling, immunotherapy and epigenetics.

For information about participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com or call 1.866.725.7110. Healthcare providers interested in learning more about Boehringer Ingelheim clinical trials in oncology can visit www.inoncologyus.com for additional information. 

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehri
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
3. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
4. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
6. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
7. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
8. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
10. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
11. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... DES MOINES, Iowa , Jan. 23, 2015  The Partnership to ... Iowa health care leaders and a new study ... prescription medications. The PFCD is a nationwide coalition working to educate ... The research released at the Capitol was focused on how the ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
(Date:1/23/2015)...  iMD Companies, Inc. (ICBU) has repositioned itself as a holding ... a foothold in the hydroponic, hemp and medical marijuana sectors. ... in the sector, and recently partnering with the Chippewa Tribe ... medical marijuana, iMD is committing to bring its vision to ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... a new blog post explaining the importance of keeping a first ... an auto insurance policy . , Clients who driver safer ... vehicle insurance policies. The safety a vehicle offers from its driver ... this, drivers should always carry a first aid kit in their ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Amneal Pharmaceuticals is,pleased to announce that it ... USP in strengths of 5mg, 10mg, 25mg and ... an AA-Rated,therapeutically equivalent alternative to Urecholine(R) (a trademark ... breakthrough for Amneal, who is,one of the very ...
... Ill., Nov. 29 Abbott (NYSE:,ABT)announced today that ... Food and Drug Administration (FDA) recommended approval for ... V is a,next-generation drug eluting stent intended for ... The FDA advisory committee voted to recommend the ...
... (NYSE: BSX ) today welcomed the recommendation ... panel to approve with conditions the,PROMUS(TM) / XIENCE(TM) ... V stent systems are identical products, sold respectively,by ... stent,systems would be covered by the same FDA ...
... Nov. 29 As early detection and treatments,improve, ... Autism and,Asperger,s Syndrome are considering higher education., ... of an aging population,with autism, others have turned ... with Autism and Developmental Disabilities (AHEADD), to,enhance their ...
... 2007 Traditionally, clinicians have relied on information ... as the primary means of assessing patients symptoms ... arise if important symptoms go unreported during those ... new study by researchers at Memorial Sloan-Kettering Cancer ...
... Experts Address Smart Solutions to Keep Program,Accessible and Affordable, ... Medical Society hosted a panel discussion with local voters ... Medicare could,leave the program after scheduled pay cuts go ... people in the program to find a doctor. But ...
Cached Medicine News:Health News:FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 3Health News:Autism U: As College Application Deadlines Near, Growing Adult Autism Population Focuses on Higher Education 2Health News:Cancer patients may benefit from reporting symptoms online in real time 2Health News:Cancer patients may benefit from reporting symptoms online in real time 3Health News:Cancer patients may benefit from reporting symptoms online in real time 4Health News:AARP Pennsylvania Hosts Panel on Strengthening Medicare 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: